Skip Navigation


PEDS Advance Access originally published online on January 25, 2006
Protein Engineering Design and Selection 2006 19(4):141-145; doi:10.1093/protein/gzj012
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/4/141    most recent
gzj012v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Roberge, M.
Right arrow Articles by Schellenberger, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roberge, M.
Right arrow Articles by Schellenberger, V.
Related Collections
Right arrow 2006
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Construction and optimization of a CC49-Based scFv-ß-lactamase fusion protein for ADEPT

Martin Roberge, Melodie Estabrook, Joshua Basler, Regina Chin, Pete Gualfetti, Amy Liu, Stephanie B. Wong, M. Harunur Rashid, Tom Graycar, Lilia Babé and Volker Schellenberger1

Genencor International, a Danisco company, 925 Page Mill Road, Palo Alto, CA 94304, USA

1 To whom correspondence should be addressed at: Volker Schellenberger, PhD, Vice President of Drug Discovery, microPROTEINS, Inc., 1455 Adams Drive, #1120, Menlo Park, CA 94025, USA; E-mail: vschellenberger{at}mproteins.com

CC49 is a clinically validated antibody with specificity for TAG-72, a carbohydrate epitope that is over-expressed and exposed on a large fraction of solid malignancies. We constructed a single chain fragment (scFv) based on CC49 and fused it to ß-lactamase. The first generation fusion protein, TAB2.4, was expressed at low levels in Escherichia coli and significant degradation was observed during production. We optimized the scFv domain of TAB2.4 by Combinatorial Consensus Mutagenesis (CCM). An improved variant TAB2.5 was identified that resulted in an almost 4-fold improved expression and 2.5° higher thermostability relative to its parent molecule. Soluble TAB2.5 can be manufactured in low-density E.coli cultures at 120 mg/l. Our studies suggest that CCM is a rapid and efficient method to generate antibody fragments with improved stability and expression. The fusion protein TAB2.5 can be used for antibody directed enzyme prodrug therapy (ADEPT).

Keywords: ADEPT/CC49/consensus mutation/scFv/thermostability

Received November 8, 2005; revised December 19, 2005; accepted December 23, 2005.

Edited by Jacques Fastrez


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.